Why the study?
Do novel lipid-lowering therapies (bempedoic acid, apoC-III inhibitors, ANGPTL3 inhibitors) reduce residual cardiovascular risk in patients with diabetic dyslipidemia?
Do novel lipid-lowering therapies (bempedoic acid, apoC-III inhibitors, ANGPTL3 inhibitors) reduce residual cardiovascular risk in patients with diabetic dyslipidemia?
Novel non-statin lipid-lowering therapies offer important adjunctive options to mitigate residual cardiovascular risk in patients with diabetic dyslipidemia who are statin-intolerant or have refractory severe hypertriglyceridemia.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Jialal et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: